Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.01.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Claire E Tocheny und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cell & Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Hauptthemen laut MEDLINE: RNA, Small Interfering, Insulin Receptor Substrate Proteins, Albumins, Breast Neoplasms. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Oligonucleotide therapeutics are a new class of drugs that enable robust and sustained modulation of gene expression. However, achieving efficient delivery of small interfering RNAs (siRNAs) to tumors is a challenge for therapy. Here, we demonstrate that fully chemically modified siRNAs conjugated with an albumin-binding dendrimer are efficiently delivered to both neoplastic and stromal/immune cells within primary triple negative breast cancer mammary tumors. siRNAs were designed to selectively target insulin receptor substrate 2 (IRS2), a signaling adapter of insulin and insulin-like growth factor (IGF) signaling that has been implicated in aggressive breast cancers. These siRNAs reduced IRS2 expression in tumor and stromal cells without causing hyperglycemia, resulting in reduced tumor growth that was associated with decreased vascularization and alterations in macrophage polarization and the expression of EMT proteins. This work demonstrates that siRNAs can be delivered to neoplastic and specific stromal populations in mammary tumors and that they can effectively and specifically silence a driver of aggressive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular, Cell & Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
- Department of Comparative Pathobiology, Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA.
- Department of Molecular, Cell & Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Electronic address: leslie.shaw@umassmed.edu.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
- Foundation for the National Institutes of Health
Zitieren
APA
Tocheny, C. E., Buchwald, J. E., Dahlke, C. D., Fakih, H. H., Morgan, J. S., Summers, A., Silva, C. A., Jackson, S. O., Lee, J. S., Card, M. A., Echeverria, D., Peterson, C., Mercurio, A. M., Khvorova, A., & Shaw, L. M. (2026). Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.01.033
Vancouver
Tocheny CE, Buchwald JE, Dahlke CD, Fakih HH, Morgan JS, Summers A, et al. Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.01.033
BibTeX
@article{Tocheny2026,
author = {Tocheny, Claire E and Buchwald, Julianna E and Dahlke, Christopher D and Fakih, Hassan H and Morgan, Jennifer S and Summers, Ashley and Silva, Christi A and Jackson, Samuel O and Lee, Ji-Sun and Card, Michael-Anthony and Echeverria, Dimas and Peterson, Cornelia and Mercurio, Arthur M and Khvorova, Anastasia and Shaw, Leslie M},
title = {Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.01.033}
}
EUVIMED